Last Updated : April 23, 2024
Details
Generic Name:
leniolisib
Project Status:
Received
Therapeutic Area:
Activated phosphoinositide 3 kinase delta syndrome
Manufacturer:
Pharming Technologies BV
Call for patient/clinician input open:
Brand Name:
TBC
Project Line:
Reimbursement Review
Project Number:
SR0792-000
Call for patient/clinician input closed:
NOC Status at Filing:
Pre NOC
Biosimilar:
No
Manufacturer Requested Reimbursement Criteria1:
Pharming requests reimbursement for leniolisib for the treatment of APDS in adults and adolescents 12 years of age and older.
Submission Type:
Initial
Fee Schedule:
Pending
Indications:
Indicated for the treatment of activated phosphoinositide 3 kinase delta syndrome (APDS) in adults and adolescents 12 years of age and older.
- The requested reimbursement criteria are provided by the applicant and do not necessarily reflect the views of CADTH. Reimbursement criteria from CADTH will be documented in the final recommendation, if applicable.
| Call for patient/clinician input open | March 07, 2024 |
|---|---|
| Call for patient/clinician input closed | April 30, 2024 |
| Submission received | April 19, 2024 |
| Submission accepted | - |
Last Updated : April 23, 2024